The central theme of this Program is improving gene transfer and gene correction in human hematopoietic stem and progenitor cells to provide more effective and safe therapies for blood cell disorders. While the concept of gene therapy using HSC to provide improved methods to treat congenital disorders has been under study for at least two decades, there have been only a small number of successful clinical applications. The techniques currently in use for gene transfer and expression in HSC are sub-optimal in most cases to yield clinical benefits. The goals of this Program are to investigate the mechanisms limiting successful clinical applications of gene transfer and to develop improved techniques which will broaden the range of diseases which may be treated effectively and safely. These advances can only be realized by combining each of these individual projects into a unified Program. This Program has three projects: 1. Selective Expansion of Hematopoietic Stem Cells and Lymphoid Progenitors, 2. Genome Modification in Human Hematopoietic Stem cells, and 3. Gene Therapy for ADA-deficient SCID. Four Cores (Administrative, Cell Isolation and Analysis, Vectors and Animals) will support the projects with integrated services for optimal quality and efficiency. The Project and Core leaders have complementary expertise in the relevant areas of experimental hematology, gene therapy, immunology, and signal transduction and have a long-standing record of interactive collaborations.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL073104-10
Application #
8513393
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Qasba, Pankaj
Project Start
2003-04-01
Project End
2014-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
10
Fiscal Year
2013
Total Cost
$1,774,220
Indirect Cost
$622,129
Name
University of California Los Angeles
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Carbonaro, Denise A; Zhang, Lin; Jin, Xiangyang et al. (2014) Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther 22:607-22
Cannon, Paula M; Kohn, Donald B; Kiem, Hans-Peter (2014) HIV eradication--from Berlin to Boston. Nat Biotechnol 32:315-6
Carbonaro Sarracino, Denise; Tarantal, Alice F; Lee, C Chang I et al. (2014) Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys. Mol Ther 22:1803-16
Hacein-Bey-Abina, Salima; Pai, Sung-Yun; Gaspar, H Bobby et al. (2014) A modified ?-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 371:1407-17
Chung, Brile; Montel-Hagen, Amélie; Ge, Shundi et al. (2014) Engineering the human thymic microenvironment to support thymopoiesis in vivo. Stem Cells 32:2386-96
Kohn, Lisa A; Seet, Christopher S; Scholes, Jessica et al. (2014) Human lymphoid development in the absence of common ?-chain receptor signaling. J Immunol 192:5050-8
Kim, William S; Zhu, Yuhua; Deng, Qiming et al. (2014) Erythropoiesis from human embryonic stem cells through erythropoietin-independent AKT signaling. Stem Cells 32:1503-14
Joglekar, Alok V; Stein, Libby; Ho, Michelle et al. (2014) Dissecting the mechanism of histone deacetylase inhibitors to enhance the activity of zinc finger nucleases delivered by integrase-defective lentiviral vectors. Hum Gene Ther 25:599-608
Gschweng, Eric; De Oliveira, Satiro; Kohn, Donald B (2014) Hematopoietic stem cells for cancer immunotherapy. Immunol Rev 257:237-49
Kim, Sanggu; Kim, Namshin; Presson, Angela P et al. (2014) Dynamics of HSPC repopulation in nonhuman primates revealed by a decade-long clonal-tracking study. Cell Stem Cell 14:473-85

Showing the most recent 10 out of 43 publications